Skip to main content
OpenTrials
Completed

NCT Number: NCT07272408

Remote Ischemic Conditioning in Patients Undergoing Primary Percutaneous Coronary Intervention

This study aimed to detect the effects of remote ischemic conditioning on infarct size, global contractility, morbidity, mortality, and renal function in patients undergoing primary percutaneous coronary intervention.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Helwan University

Helwan, 11795, Egypt

About this study

Myocardial infarction (MI) generally refers to segmental (regional) myocardial necrosis, typically endocardial in location, secondary to occlusion of an epicardial artery.

Primary percutaneous coronary intervention (PPCI) is a reperfusion therapy that is carried out in patients who usually have ST-segment elevation MI (STEMI) within a specific time window.

During ischemia, metabolic acidosis occurs due to anaerobic metabolism, and ischemic injury ensues. After restoration of blood supply, reactive oxygen species (ROS) production and local inflammation increase secondary injury.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age more than 18 and less than 75 years old.
  • Both sexes.
  • Patients with new ST-segment elevation at the J-point in V1:V6 leads with the cut-point: ≥ 1mm other than leads V2-V3 where the following cut-points apply: ≥ 2mm in men ≥ 40 years; ≥ 2.5mm in men < 40 years, or ≥ 1.5mm in women regardless of age.
  • Patients with new left bundle branch block (LBBB).

Exclusion criteria

  • ST-segment elevation myocardial infarction (STEMI) with cardiogenic shock.
  • Severe comorbidities (uncontrolled hypertension, morbid obesity, recent cerebrovascular stroke, respiratory failure, sepsis, and stage 4 & 5 malignancy).
  • End-stage renal disease on hemodialysis.
  • Previous coronary artery bypass graft surgery (CABG).
  • Myocardial infarct within the previous 30 days.
  • Multi-vessel coronary artery disease.
  • Failure of culprit vessel recanalization.
  • Conditions precluding use of remote conditioning ie: paresis of upper limb.
  • Life expectancy of less than 1 year due to a non-cardiac pathology.
  • Patients who receive nephrotoxic drugs such as non-steroidal anti-inflammatory drugs and aminoglycosides.

Treatment and study plan

Remote Ischemic conditioning

Procedure

Remote ischemic conditioning (RIC) was applied to those patients.

Normal primary percutaneous coronary intervention

Procedure

Patients followed the standard primary percutaneous coronary intervention pathway.

Primary outcomes

  1. Cardiac death

    Time frame: 1 month post-procedure

    Incidence of cardiac death was recorded.

Secondary outcomes

  1. Hospitalization for heart failure

    Time frame: 1 month post-procedure

    Hospitalization for heart failure post-randomization in the intention-to-treat population was assessed.

  2. Contrast induced nephropathy

    Time frame: 1 month post-procedure

    Contrast induced nephropathy was assessed.

  3. Incidence of adverse events

    Time frame: 1 month post-procedure

    Incidence of adverse events was recorded.

  4. Renal impairment

    Time frame: 1 month post-procedure

    Renal impairment was recorded.

Sponsors and collaborators

Lead sponsor

Helwan University

Other

Registry information

Official study title

Impact of Remote Ischemic Conditioning in Patients Undergoing Primary Percutaneous Coronary Intervention

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Dec 9, 2025
Registry last updated
Dec 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.